Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947424 | 0.86 | NLRP3 (0.34) | NLRP3 | |
| SCHEMBL9452630 | 0.80 | MAPT (0.33) | MAPTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL9918135 | 0.75 | — | — | |
| SCHEMBL14911002 | 0.74 | — | — | |
| SCHEMBL9947422 | 0.74 | NLRP3 (0.43) | NLRP3 | |
| SCHEMBL3285840 | 0.69 | NLRP3 (0.33) | NLRP3 | |
| SCHEMBL28392433 | 0.69 | NLRP3 (0.33) | NLRP3 | |
| SCHEMBL9918134 | 0.67 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL3289507 | 0.67 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL9921580 | 0.67 | NEK2 (0.38) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140308260-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | EPICENTRX, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013052803-A2 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | RADIORX, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012078992-A1 | ORGANONITRO COMPOUNDS FOR USE IN TREATING NON-HODGKIN'S LYMPHOMA AND LEUKEMIA, AND METHODS RELATING THERETO | RADIORX, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308260-A1 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | HBB, HBG2, HBZ | MAPT 4665/4885ALDH1A1 1464/4885HPGD 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.